TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Facet Biotech Should Dig in Its Heels over Biogen Bid EP Vantage submits:While most shareholders would, under normal circumstance, jump at a takeover bid that carried a 64% premium, Facet Biotech (FACT) appears to be sensibly holding out for better terms following an unsolicited $355m approach from Biogen Idec (BIIB).Despite the initially impressive share price premium, the offer from Biogen does look a little on the light side when you consider just how much cash Facet, which was spun out of PDL BioPharma last year, has on its balance sheet. Standing at $371m as of June, when this is taken into account Biogen is technically making money by bidding for the group.Complete Story » seekingalpha.com |
Senate Panel to Vote Tuesday on Bill The Senate Finance Committee will vote next Tuesday on a $829 billion health-care bill, after months of efforts to gain consensus on the massive overhaul. online.barrons.com |
Neurocrine Biosciences, Inc. Q3 2009 Earnings Conference Call Neurocrine Biosciences, Inc. (NBIX)Q3 2009 Earnings CallOctober 29, 2009 08:30 a.m. ET Complete Story » seekingalpha.com |
Pelosi Open to Medicare Deal Pelosi expressed support for a Senate Democratic plan to expand Medicare, raising the prospect of a bicameral agreement on a health bill. online.wsj.com |
Drug to Aid MS Patients Wins Approval The FDA approved a new drug from Acorda Therapeutics to improve walking in patients with multiple sclerosis. online.wsj.com |